Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara; 'ONO') announced today that it has agreed to transfer the manufacturing and marketing approval authorization (MMAA) for Kinedak tablets which ONO has retained, as from April 1st, 2021 to Alfresa Pharma Corporation (Osaka, Japan; President, Koichi Shimada; 'Alfresa Pharma').

Kinedak tablets, for which the MMAA will be transferred this time, is a first-in-class ethical drug created by ONO and has been used for the treatment of many patients with diabetic peripheral neuropathy.

From now on, ONO and Alfresa Pharma will work together toward the transfer, to ensure a stable supply of Kinedak tablets and to contribute the activities for proper use of the product through the provision and collection of product information.

Contact:

Email: publicrelations@ono.co.jp

(C) 2021 Electronic News Publishing, source ENP Newswire